June 2005

  

"ISPOR e-BULLETIN" provides updates of recent ISPOR activities and events. For detailed information on ISPOR activities, members are encouraged to go to www.ispor.org.

 

Please share these new ISPOR activities with your colleagues.

  eBulletin Index

June 2005

 

  

ISPOR e-BULLETIN provides updates of recent ISPOR activities and events. For detailed information on ISPOR activities, members are encouraged to go to www.ispor.org.

 

Please share these new ISPOR activities with your colleagues.

 

 

NEW THIS MONTH

**NEW** 10th Annual Meeting Photo Gallery

**NEW** 10th Annual International Meeting Contributed Paper Award Recipients

**NEW** Value in Health Vol. 8 No. 3 (May/June 2005) (Annual Meeting Abstract Issue now includes research papers)

**NEW** Value In Health Features New “On-Line Early” Manuscripts

**NEW** New ISPOR Student Network Chair

**NEW** ISPOR Special Interest Group (SIG) Updates

**NEW** 7 New Positions at the ISPOR website

      

 ISPOR ONGOING ACTIVITIES

 

1.       Publications

2.       Meetings and Congresses

3.       Educational Activities

4.       Student News

5.       ISPOR Special Interest Groups

6.       Committee and Task Force Activities

7.       Hot Topics

8.       Important Dates to Remember

8.       Asia Consortium and Local Chapter News

10.    Employment in Pharmacoeconomics and Outcomes Research

11.    Membership

 


  1. PUBLICATIONS

Top

 

VALUE IN HEALTH

 

**NEW** Value in Health: Volume 8, Issue 3, May/June 2005 is online at: http://www.ispor.org/valueinhealth_index.asp.  The following is the TABLE OF CONTENTS for Value in Health Volume 8, Issue 3, May/June 2005:

 

FORWARD

Josephine Mauskopf

 

EMPIRICAL

Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic Modeling Study

Talitha L. Feenstra, Heleen H. Hamberg-van Reenen, Rudolf T. Hoogenveen, Maureen P.M.H. Rutten-van Molken

 

Economic and Utilization Outcomes Associated with Choice of Treatment for Venous Thromboembolism in Hospitalized Patients

Kevin K. Knight, John Wong, Ole Hauch, Gail Wygant, Daniel Aguilar, Joshua J. Ofman

 

Managing Prices for Hospital Pharmaceuticals: A Successful Strategy for New Zealand?

June M. Tordoff, Pauline T. Norris, David M. Reith

           

The Economic Value of Childhood Varicella Vaccination in France and Germany

Laurent Coudeville, Alain Brunot, Thomas D. Szucs, Benoit Dervaux

 

POLICY AND APPLICATION

Federal Sponsorship of Cost-Effectiveness and Related Research in Health Care: 1997-2001

Joanna E. Siegel, Sepheen C. Byron, William F. Lawrence

 

CONTRIBUTED PODIUM PRESENTATIONS

Value in Health; Volume 8, Issue 3, Page 237

CONTRIBUTED POSTER PRESENTATIONS

Value in Health; Volume 8, Issue 3, Page 258

DISCLOSURE INFORMATION

Value in Health; Volume 8, Issue 3, Page 420

ABSTRACTS INDEX

Volume in Health; Volume 8, Issue 3, Page 426

 

      **NEW** VALUE IN HEALTH FEATURES NEW “ON-LINE EARLY” MANUSCRIPTS

Beginning with Volume 8, Issue 4 of Value in Health, our "On-Line Early" format will be featured.

Available later this month, this new feature will allow you to view articles from upcoming issues approximately 1

month before their scheduled issue release date. To view these "On-Line Early" articles, simply

go to  http://www.ispor.org/valueinhealth_index.asp, log on using your membership information,

and follow the link.

 

Featured in Volume 8, Issue 4…

 

EMPIRICAL

OVERACTIVE BLADDER/URINARY INCONTINENCE (OAB/UI) DRUG THERAPY DISCONTINUATION MAY SIGNIFICANTLY INCREASES THE RISK OF URINARY TRACT INFECTION IN CHRONIC OAB/UI PATIENTS

Yanni F. Yu, Michael B. Nichol, Andrew P. Yu, and Jeonghoon Ahn

 

Overactive bladder and urinary incontinence are conditions referring to any bladder dysfunction of storing and voiding urine. They can be transient but millions of patients, especially seniors and females, are suffering from a chronic OAB/UI. Drug therapy has been a popular treatment option for OAB/UI patients but compliance and persistence during the course of drug therapy has been a major issue in treating OAB/UI. A recent study, “Persistence and Adherence of Medications for Chronic Overactive Bladder/Urinary Incontinence in the California Medicaid program” published in Value in Health, reports that, among the chronic OAB/UI patients, the patients who discontinued drug therapy have significantly higher risk of having an incidence of urinary tract infection (UTI) than who did not. The researchers of the University of Southern California looked at 2,496 randomly selected chronic OAB/UI patients in California Medicaid (MediCal) program for compliance patterns and associated clinical outcomes. “We found that the patients who discontinued OAB/UI drug therapy have 37% higher risk of UTI incidence in six-month follow-up period,” says Jeonghoon Ahn, the corresponding author of this research. He emphasized that the persistence and treatment discontinuation are big problems for the OAB/UI patients not only in terms of UTI incidence but also in terms of many other negative impacts.

 

HIGHER QUETIAPINE DOSES MAY BE MORE EFFECTIVE

Frank Gianfrancesco, Ruey-hua Wang MS, and Jacqueline Pesa

 

Quetiapine, an atypical antipsychotic, is an effective and well tolerated agent for the treatment of schizophrenia and acute mania associated with bipolar disorder.  However, broad dosage guidelines may have encouraged quetiapine initiation schedules that are too conservative to be optimally effective. This possibility was investigated in a recent study, “Relationship between initial quetiapine dose and effectiveness as reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder,” published in Value and Health, Volume 8, Issue 4. Using a large commercial claims database and controlling for patient differences, Gianfrancesco et al., of HECON Associates and AstraZeneca, found that patients initiated on higher doses of quetiapine had lower subsequent levels of mental health service use.  Hospitalizations were mainly affected among schizophrenia patients while bipolar patients experienced reduced ambulatory services.  Consistent with these findings, patients started on higher doses were also less likely to require later upward dose adjustments.  Large numbers of both schizophrenia and bipolar patients were given quetiapine doses that were below the lowest recommended level (150 mg/d).  While the study does not and cannot identify appropriate quetiapine dosage levels for commercially insured patients (who may be less severely ill), it does suggest that more aggressive dosing may be more effective.

 

HEALTH CARE COST, QUALITY, AND OUTCOMES: ISPOR BOOK OF TERMS

  

"The ISPOR Book of Terms has been a real hit with our customers and employees alike.  It fills a gap for those who are new to Outcomes." Jenifer Ehreth, PhD, Director Reimbursement for Europe, Middle East and Africa Medtronic Europe

 

This ISPOR publication includes more than 100 detailed monographs covering over 400 terms used in health care delivery, management, and regulation, as well as health care outcomes research including clinical, economic, and quality-of-life research terms. ISPOR member discounted price is $36.00; a 40% discount!  Student/Library/Academic discounted price: $33.00 (a 45% discount). On-line ordering is now available at: http://www.ispor.org/publications/lexicon_index.asp.  Contact Stephen Priori at spriori@ispor.org for information on orders over 100. 

 


  

  1. ISPOR MEETINGS AND CONGRESSES

Top

   

ISPOR EIGHT ANNUAL EUROPEAN CONGRESS

      6-8 November 2005 Palazzo Degli Affari, Florence , Italy

     "INCORPORATING VALUES INTO HEALTH CARE DECISIONS"

 

**Abstract Submission Deadline: 20 June 2005

June 20 at 11:59 PM US Pacific Daylight Savings Time is the deadline to submit an abstract for presentation at the ISPOR 8th Annual European Congress.  All abstract submissions are online:  http://www.ispor.org/congresses/italy1105/abstr_instr.asp

 

Contributed Research topics:

**Clinical Outcomes Studies

**Cost Studies

**Patient Reported Outcomes Studies (Quality of Life, Utility, Treatment/Patient/Work Satisfaction, Preference Studies)

**Health Care Use & Policy Studies

**Method Studies & Concepts

Contributed Workshop topics:

**Clinical study methodology issues including pharmacoepidemiology

**Cost study methodology issues

**Quality of life study methodology issues including patient reported outcomes

**Preference-based studies methodology issues including utility studies

**Drug/device coverage research issues

**Health care policy development issues using outcomes research

**Risk assessment/risk management issues

**Compliance issues

**Patient registry development issues

Contributed Issue Panel

Submissions are accepted on (but not excluded to) the following topics:

**Pharmacoeconomic / Health Economic Study Methodology Issues

**Quality of Life / Patient-Reported Outcomes Study Methodology Issues

**Utility (Preference-based) Study Methodology Issues

**Clinical Outcomes

**Health Policy

**Health Care Reimbursement / Coverage Issues

**Risk Assessment Study Issues

**Use of Health Economic/Pharmacoeconomic Information by Decision-Makers

 

First Plenary Session:

Patient Values and Societal Values: How to Measure and Compare Outcomes
and What Considerations for the Different Audiences

http://www.ispor.org/congresses/italy1105/100605.asp

 

Second Plenary Session:

Health Care Decision Makers Facing the Budget Allocation Dilemma:

Compressing Mortality vs. Compressing Morbidity

http://www.ispor.org/congresses/italy1105/100705.asp

 

Third Plenary Session:

The Value of Safety: A Critical Issue All Along the Development
and Marketing of Pharmaceuticals

http://www.ispor.org/congresses/italy1105/100805.asp

 

      Exhibitor Opportunities available at:

 

      Sponsorship Opportunities available at:

 

For more details about the Congress, go to: http://www.ispor.org/congresses/italy1105/index.asp

 

ISPOR 10TH ANNUAL INTERNATIONAL MEETING–RECORD ATTENDANCE!!

      May 15-18, 2005, Marriott Wardman Park Hotel, Washington, DC, USA

 

Celebrating 10 years of global pharmacoeconomics awareness, the ISPOR Annual International Meeting celebrated it’s 10th anniversary at the Marriot Wardman Park Hotel, in the nation’s capitol, Washington, DC, USA, and once again successful.  Over 1300 attendees from 33 different countries joined in a week’s-long worth of festivities, as well as participated in the technical sessions and scientific matter in which attendees have grown accustomed to at ISPOR Annual International Meetings.

 

**NEW** Photo Gallery

http://www.ispor.org/meetings/washington0505/pg/pages/index.html

 


 

  1. EDUCATION ACTIVITIES

Top

           

ISPOR SHORT COURSESISPOR 8TH ANNUAL EUROPEAN CONGRESS

13 ISPOR SHORT COURSES prior to the ISPOR 8th Annual European Congress 6-8 November NOW available at: http://www.ispor.org/congresses/italy1105/index.asp

 

ISPOR Distance Learning Program Modules

ISPOR Distance Learning Program

  

The following module topics are currently available (total of 40 modules):

·      Pharmacoeconomics

·      Pharmacoeconomic Evaluations & Methods

·      Cost-Effectiveness Analysis

·      Cost-Benefit Analysis

·      Cost-Utility Analysis

·      Patient-Reported Outcomes (Utilities, Health-Related Quality Of Life, Treatment  Satisfaction, Treatment Adherence, Patient Preferences)

·      Study Design in Pharmacoeconomics

·      Guidelines and Reference Standards

·      Pharmacoeconomics in Drug Development, Reimbursement and Marketing

 


 

  1. STUDENT NEWS

Top

 

**NEW** ISPOR STUDENT NETWORK CHAIR

Josh Epstein, BA, BS, The University of Southern California, Los Angels, CA USA, is the newly elected chair for the Student Network for 2005-2006.

 

For more details on the ISPOR Student Network, please visit: http://www.ispor.org/student/student_index.asp        


  

  1. ISPOR SPECIAL INTEREST GROUPS (SIG)

Top

 

VALUE-BASED REIMBURSEMENT SIG

 

The Value-based Reimbursement SIG held an Open Meeting for all interested ISPOR members and a breakfast for SIG leadership members during the ISPOR 10th Annual International Meeting.  The mission, working groups, leadership and future activities of the SIG were presented during the meeting while the breakfast was an opportunity for the Working Group Chair people to meet with leadership members, formulate their plans and define the tasks needed to reach their goals.

 

UPCOMING: This SIG is planning an event for the ISPOR 8th Annual European Congress.


UPCOMING: Each of the working groups is holding a teleconference in the 2nd or 3rd week of June with their members.   

 

Value Based Reimbursement SIG Working Groups:

· Evidence and Payer Decision-making Working Group
Co-Chair: Nancy Risebrough
Senior Associate, HOPE Research Centre, Toronto, Ontario, Canada
Co-Chair: Michael Halpern MD, MPH, PhD, Chief Scientist, Exponent, Alexandria, VA, USA

· Global Reimbursement Strategies Working Group
Co-Chair: Geoffrey Wilson DPhil, BSc, MSc, PhD, Managing Director, ValuemoniX, Penn, UK  
Co-Chair: Jennifer Stephens PharmD, Senior Clinical Consultant, PharMerit, Bethesda, MD USA

 

· Global Reimbursement Trends Working Group
Co-Chair: Stefan Holmstrom BSc, MSc
, Manager, Strategic Pricing & Reimbursement, Allergan, Biot, France
Co-Chair: Kevin Mayo PhD, Head, Global Strategic Pricing & Health Economics (NS & ID), Novartis Pharmaceuticals, Basel, Switzerland

 

· Reimbursement Literature Working Group
Co-Chair: Paul Trueman MA, Sales & Marketing Director, York Health Economics Consortium, University of York, Heslington, York, UK
Co-Chair: Parthiv Mahadevia MD, MPH, Associate Director, Payment and Coverage Group, Amgen, Inc., Washington, DC, USA

 

· Payer-oriented Evidence Guidelines Working Group
Co-Chair: James Mackay MD
, Medical Director, Providence Health Plans, Beaverton, OR, USA
Co-Chair: Joseph Singer MD, Vice President, HealthCore, Inc, Wilmington, DE, USA

 

For more details on this SIG or to join as a reference or leadership group member, please visit: http://www.ispor.org/sigs/reimbursement.asp

 

HEALTH TECHNOLOGY ASSESSMENT SIG

 

The Health Technology Assessment SIG held an Open Meeting for all interested ISPOR members and a breakfast for SIG leadership members during the ISPOR 10th Annual International Meeting.  The mission, working groups, leadership and future activities of the SIG were presented during the meeting while the breakfast was an opportunity for the Working Group Chair people to meet with leadership members, formulate their plans and define the tasks needed to reach their goals.

 

UPCOMING: This SIG is planning an event for the ISPOR 8th Annual European Congress.

 

UPCOMING: Each of the working groups is holding a teleconference in the 2nd or 3rd week of June with their members. 

 

HTA SIG Working Groups:


*HTA Methodology Working Group

Chair: Francis Pang BSc, MSc, PhD, Head of Health Economics, Abbott Laboratories, Maidenhead, UK

*HTA in Reimbursement Economics Working Group
Co-Chair: Jalpa Doshi PhD, Health Services Research Scientist, General Internal Medicine, University of Pennsylvania, Philadelphia, PA USA
Co-Chair: Bonnie Handke RN, Sr. Reimbursement Manager, Medtronic, Minneapolis, MN, USA

*Applied HTA Working Group
Co-Chair: Uwe Siebert MD, MPH, MSc
, Director, Cardiovascular Research Program, MGH Institute for Technology Assessment, Harvard Medical School, Boston, MA, USA
Co-Chair: Philip Booth MS, Director of Health Technology Appraisal, Novartis Pharmaceuticals, Frimley, Camberley, UK

 

*HTA to Support Marketing Initiatives Working Group

Co-Chair: Sheryl Szeinbach BS, MS, PhD, RPh, Professor, College of Pharmacy, Ohio State University, Columbus, OH, USA

Co-Chair: Noreen Sullivan BS, Vice President, Aequitas, San Diego, CA, USA

 

For more details on this SIG, please visit: http://www.ispor.org/sigs/hta.asp

 

CLINICAL PRACTICE SIG

 

***NEW*** SIG Chair: Peter K. Wong PhD, MBA, RPh, Vice President, Clinical Effectiveness & PI, Good Samaritan Hospital, Dayton, OH, USA

UPCOMING: Look for new developments with this SIG.


The Clinical Practice SIG held a forum during the ISPOR 10th Annual International Meeting
.  The topic was Applying Pharmacoeconomic Principles in Clinical Practice . . . Noble Enterprise or Pipe Dream?    
   and
the Value Proposition to Payers & Providers:  Do Pharmacoeconomic Studies Meet the Needs of Decision Makers?

Stakeholder perspectives (payer, hospital and individual provider) were presented as well as real-world examples of how outcomes research and pharmacoeconomic principles are applied across different medical centers, in Pharmacy & Therapeutics Committees and how patient outcomes can be used to develop practice guidelines and evaluate treatment outcomes.   An audience discussion about restrictions that currently prevent the widespread usage of outcomes research and pharmacoeconomics in decision making along with suggested measures to take to change the current situation closed the session.

 

Clinical Practice SIG also held a workshop.  The topic was Standardized Reporting Format for Outcomes Research or Economic Evaluation and a System to Measure the Strength of Evidence of Studies

 

If you would like to get involved in this SIG, please review this webpage and join as a leadership group or reference group member. http://www.ispor.org/sigs/sigsindex.asp

 

PATIENT REGISTRY SIG

 

Patient Registry SIG held a forum during the ISPOR 10th Annual International Meeting.  The topic was Patient Registries: Opportunity and Responsibility.  Key issues, including the industry's role in sponsoring post-approval registries that capture "real world" clinical, economic, and humanistic data and other evaluations critical for a more accurate characterization of how drugs and devices are utilized in actual medical practice, were discussed.  In addition, the findings from the Patient Registry survey were presented and the Working Group Chairs commented on issues involving commercialization, safety surveillance, analytical methods, technology, and global initiatives. 

 

UPCOMING: The PR SIG Working Groups are moving forward with their best practices / guidance White Paper drafts.  If you would like to get more involved, please review the webpage below and join as a reference group or leadership group member http://www.ispor.org/sigs/patient_registr.asp

 

QUALITY OF LIFE SIG

 

**NEW** SIG Chair: Judith Barr ScD, Med, Associate Professor, School of Pharmacy,  Northeastern University & Director, National Education and Research Center for Outcomes Assessment, Boston, MA, USA

 

The Quality of Life SIG held a forum during the ISPOR Annual Meeting.  The topic was: Health Status and Patient Reported Outcomes / Quality of Life Measures in the ‘Real World'   Included in the discussion: Benefits of Using ‘Real World' Quality of Life/Patient Reported Outcomes, Challenges and Limitations of ‘Real World' Quality of Life/Patient Reported Outcomes, Methods and Best Practices for ‘Real World' Quality of Life/Patient Reported Outcomes Studies, and Next Steps for ISPOR

 

The Quality of Life SIG also held an Open Meeting.  The mission, working groups, leadership and future activities of the SIG were presented.   

 

If you would like to get more involved with this SIG and a working group, please review the webpage below and contact the SIG Chair, Judith Barr at j.barr@neu.edu.

 

For more details on this SIG, please visit: http://www.ispor.org/sigs/qol.asp

 
MEDICATION COMPLIANCE SIG

Three successful workshops were presented at the ISPOR 10th Annual International Meeting by the Medication Compliance SIG. The Chairs and Leadership Group members also participated in working breakfasts and dinners during the Meeting, further progressing the goals of this SIG.

 

The Medication Compliance Forum during the 10th Annual International Meeting was well attended.  The progress and future goals of the four working groups: Issues & Methods WG; Analyses Standards WG; Education Working Group; and Economics of Medications Compliance WG were presented and discussed, followed by discussion and questions.

 

      UPCOMING:  Workshops will be presented at the 8th European Congress

 

If you would like to join this SIG as a leadership group or reference group member please e-mail medcomsig@ispor.org

 

For more details on this SIG, please visit: http://www.ispor.org/sigs/medication.asp

 

RETROSPECTIVE DATABASE SIG

The Retrospective Database SIG held its first Forum at the ISPOR 10th International Meeting in Washington, DC on Tuesday, May 17 to present ISPOR Digest of International Databases questionnaire form and to get feedback from the audience.  The Working Groups also participated in breakfasts to discuss the goals of the SIG.

 

For more details on this SIG, please visit: http://www.ispor.org/sigs/retrospective_db.asp

 

RISK MANAGEMENT SIG

 

The Risk Management SIG presented two workshops during the ISPOR 10th Annual International Meeting.   The first workshop topic was balancing risks and benefits of healthcare treatments in the 21st century.  Areas of risk/benefit assessment were explored and how to balance the two.  An interactive group case study was performed following the presentation.

The second workshop topic was ISPOR member perspectives: How do individuals perceive risks and benefits of pharmaceuticals in comparison with other non-medical activities.  This workshop exposed and analyzed the results of a healthcare survey given to ISPOR membership.  Interesting findings included: US v. non-US comparisons of risk assessment and the amount of effect that individual side-effect experiences had on the perception of risk associated with other pharmaceuticals.

 

For more details on this SIG, please visit: http://www.ispor.org/sigs/rm.asp and join as a reference or leadership group member.

 

MANAGED CARE SIG

 

For more details, please visit: http://www.ispor.org/sigs/sigsindex.asp

 

Special Interest Group membership is open to ALL ISPOR members. To JOIN any SIG: http://www.ispor.org/sigs/joinsig.htm

 


 

  1. ISPOR BOARD, COMMITTEE, AND TASK FORCE ACTIVITIES

Top

           

AWARD COMMITTEE ACTIVITIES

 

**NEW** ISPOR TENTH ANNUAL INTERNATIONAL MEETING CONTRIBUTED PAPER AWARDS RECIPIENTS

 

BEST CONTRIBUTED PAPER AWARDS PODIUM PRESENTATIONS

GENERAL


MS3

ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTIN® TABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE
Marshall DA1, Strauss ME2, Pericak D1, Buitendyk M1, Codding C3, Kim S2, Torrance G1
,
1Innovus Research Inc, Burlington, ON, Canada; 2Purdue Pharma L.P, Stamford, CT, USA; 3Oklahoma Sports, Oklahoma City, OK, USA

 

IN1

COMPARISON OF RISK FACTORS FOR BLOOD STREAM CANDIDEMIA AND BACTEREMIA IN HOSPITALIZED PATIENTS
Amrutkar PP, Rege M, Kumar N, Kachroo S, Garey KW

University of Houston, College of Pharmacy, Houston, TX, USA


QL2

NEW WEIGHTS FOR OLD: A SCALE OF VALUES FOR EQ-5D HEALTH STATES
Kind P, Macran S, Hennessy S

University of York, York, UK


NEW INVESTIGATOR


HP4

POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING FOR ELDERLY AMBULATORY PATIENTS IN REGIONE EMILIA ROMAGNA, ITALY

Maio V, Yuen EJ, Novielli KD, Rabinowitz C, Louis DZ

Jefferson Medical College, Philadelphia, PA, USA

 

MS4

THE COST-EFFECTIVENESS OF ADDING INFLIXIMAB TO USUAL THERAPY IN THE TREATMENT OF PSORIATIC ARTHRITIS
Marra CA1, Maetzel A2, Farewell VT3, Rashidi AA1, Shi P1, Antoni C4, Wong JB5, Gladman DD6

1University of British Columbia, Vancouver, BC, Canada; 2Toronto General Research Institute, Toronto, ON, Canada; 3Institute of Public Health, Cambridge, UK; 4Schering-Plough Corporation, Kenilworth, NJ, USA; 5Tufts-New England Medical Center, Boston, MA, USA; 6Toronto Western Research Institute, Toronto, ON, Canada

 

IN4

COST EFFECTIVENESS OF HIV TREATMENT INNOVATIONS OF GREATER EFFICACY THAN HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
Snedecor SJ1, Hartzema A1, Schiller KC2

1Pharmacy Health Care Administration, Gainesville, FL, USA; 2University of Florida, Gainesville, FL, USA


STUDENT


CN3

ONCOLOGISTS' COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCER THERAPIES
Nadler E1, Eckert B2, Neumann P2

1Dana Farber Cancer Institute, Boston, MA, USA; 2HarvardUniversity, Boston, MA, USA

 

MH4

EFFECT OF SECOND-GENERATION ANTIDEPRESSANT DISCONTINUATION ON DEPRESSIVE RELAPSE IN ADULT PATIENTS WITH BIPOLAR DEPRESSION
Fu AZ, Christensen DB, Hansen RA

University of North Carolina, Chapel Hill, NC, USA

 

CS8

ECONOMIC EVALUATION OF ONDANSETRON VERSUS DIMENHYDRINATE FOR PREVENTION OF POSTOPERATIVE VOMITING IN CHILDREN
Piwko C1, Lasry A1, Alanezi K1, Coyte PC1, Ungar WJ2

1University of Toronto, Toronto, ON, Canada; 2The Hospital for Sick Children, Toronto, ON, Canada


BEST CONTRIBUTED PAPER AWARDS POSTER PRESENTATIONS

GENERAL


PCN1

META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS FOR COLORECTAL CANCER

Slivinskas JC1, Gagnon YM1, Levy AR2, Enns RA3
1 Oxford Outcomes, Vancouver, BC, Canada; 2 University of British Columbia, Vancouver, BC, Canada; 3 St. Paul's Hospital, UBC, Vancouver, BC, Canada

 

PHP49

BRIEF SUMMARY FORMATS OF DTCA TO IMPROVE CONSUMER COMPREHENSION

Sansgiry SS, Kawatkar AA
University of Houston, Houston, TX, USA

 

PHP34

AN ASSESSMENT OF THE ASSOCIATION BETWEEN UNDERLYING WORKER MEDICAL CONDITIONS AND WORKER ABSENTEEISM IN THE US

Mavros P1, Pietri G2
1 Merck & Co., Inc, Whitehouse Station, NJ, USA; 2 Rutgers University, Piscataway, NJ, USA

 

NEW INVESTIGATOR

PDB46

WILLINGNESS-TO-PAY FOR INHALED INSULIN – A CANADIAN PERSPECTIVE

Sadri H
Health Outcome and Pharmacoeconomics Research Centre, Toronto, ON, Canada

 

PDB25

DEPRESSION IN PATIENTS WITH TYPE 2 DIABETES: IMPACT ON UTILIZATION PATTERNS AND ADHERENCE TO ORAL HYPOGLYCEMIC AGENTS

Kalsekar I1, Madhavan SM2, Amonkar M3, Douglas S2, Makela E2, Scott V2
1 Butler University, Indianapolis, IN, USA; 2 West Virginia University, Morgantown, WV, USA; 3 GlaxoSmithKline, Collegeville, PA, USA

 

PCV16

INCREMENTAL EFFECTS OF CONCURRENT PHARMACOTHERAPEUTIC REGIMENS FOR HEART FAILURE ON HOSPITALIZATIONS AND COSTS

Skrepnek GH1, Abarca J1, Malone DC1, Armstrong EP1, Shirazi FM2, Woosley RL2
1 University of Arizona College of Pharmacy, Tucson, AZ, USA; 2 University of Arizona College of Medicine, Tucson, AZ, USA

 

STUDENT

PCV33

MONITORING OF LIPID LEVELS AND ADVERSE EVENTS AMONG TEXAS MEDICAID PATIENTS ON STATIN THERAPY

Dastani H1, Shepherd M1, Sasane R2
1 University of Texas, Austin, TX, USA; 2 AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

 

PDB45

QUALITY OF LIFE (SF12), CLINICAL OUTCOMES, AND COMORBID CONDITIONS IN PATIENTS WITH TYPE-2 DIABETES: A POPULATION STUDY

Sundaram M, Kavookjian J
West Virginia University, Morgantown, WV, USA

 

PCN2

SURVIVAL ANALYSIS OF PAIN RELIEF PROVIDED BY DOXEPIN ORAL RINSE FOR ORAL MUCOSITIS PATIENTS

Epstein JD1, Epstein JB2, Epstein MS3, Oien HJ4, Truelove EL5
1 University of Southern California, Los Angeles, CA, USA; 2 University of Illinois, Chicago, IL, USA; 3 Fred Hutchison Cancer Research Center, Seattle, WA, USA; 4 Private General Dental Practice, Tualatin, OR, USA; 5 University of Washington, Seattle, WA, USA

 

2005 ISPOR SCIENTIFIC AWARDEES: http://www.ispor.org/awards/index_.asp

 

2005 ISPOR SERVICE AWARDEES: http://www.ispor.org/awards/service/service.asp

 

2005 ISPOR DISTINGUISHED SERVICE AWARDEES: http://www.ispor.org/awards/service/distinguish.asp

 

ISPOR TASK FORCE: USING "REAL WORLD" DATA IN COVERAGE AND REIMBURSEMENT DECISIONS

  

For more details, including a draft outline of this final paper, and a list of core group members, go to: http://www.ispor.org/workpaper/real_world_data.asp

 

  1. HOT TOPICS

Top

 

PRESCRIPTION DRUG PURCHASING SIMPLIFIED THROUGH NEW TECHNOLOGIES

CMS AWARDS CONTRACT FOR NEW SYSTEMS TO COORDINATE BENEFICIARY COVERAGE

May 23, 2005 – The Centers for Medicare & Medicaid Services (CMS) has taken another step to make it easier for Medicare beneficiaries to get prescription drugs from their local pharmacies. This action will allow pharmacists to use their existing computer systems to determine which Medicare drug plan to bill and whether the beneficiary has other drug coverage, all while the beneficiary is at the counter. Medicare beneficiaries will begin to receive their prescription drugs under the new benefit starting January 1, 2006.

For full text of the article, see: http://www.cms.hhs.gov/media/press/release.asp?Counter=1466


 

  1. IMPORTANT DATES TO REMEMBER

Top

  

June 20, 2005 Abstract Submission deadline for the ISPOR 8th Annual European Congress.

 

1 July 2005 Abstract Submission begins for the ISPOR 2nd Asia-Pacific Congress.

 

8-11 November 2005 – ISPOR 8th European Congress, Palazzo Degli Affari, Florence, Italy

 

5-7 March 2006 – ISPOR 2nd Asia-Pacific Conference, Shanghai Worldfield Convention Hotel, Shanghai, China

 

20-26 May 2006 – ISPOR 11th Annual International Meeting, Marriott Philadelphia, Philadelphia, PA


 

  1. ASIA CONSORTIUM AND LOCAL CHAPTER NEWS

Top

 

ISPOR ASIA CONSORTIUM

 

For more details on this consortium, please visit: http://www.ispor.org/consortiums/asia.asp

 

For more details on ISPOR local chapters, please visit: Regional Chapters

 

ISPOR 2ND ASIA-PACIFIC CONFERENCE

The ISPOR 2nd Asia-Pacific Conference will be held in Shanghai, China, 5-7 March 2006. Abstract submission begins 1 July 2005 and ends 3 October 2005.  Early registration deadline is 5 February 2006.

 

For more details on the 2nd Asia-Pacific Conference, please visit: http://www.ispor.org/conferences/shanghai0306/index.asp


  1. EMPLOYMENT

Top

**NEW** 7 NEW POSITIONS AT THE ISPOR WEBSITE: Careers

 

Advertise your positions on ISPOR Website (~1 million hits per month)

 

INTERNSHIPS

Visit ISPOR's Internship-Professional Recruitment Assistance Program (I-PRAP) at

 

STUDENTS: Post your CVs/resumes for employers to view and search for internship positions available.  Nine student resumes posted! 

 

EMPLOYERS: Post your Intern positions for FREE and access CVs/resumes from students.

 

If you have any questions, please contact: iprap@ispor.org.


 

  1. ISPOR MEMBERSHIP

Top

 

Update your email address at https://www.ispor.org/members/MemberProfile.aspx! Your email address is required as part of your log in information in the members only section of the ISPOR website.

 

 



eBulletin Index